| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 860 | 1,310 | 2,880 | 1,350 | 0 |
| Sales Growth | -34.35% | -54.51% | +113.33% | unch | unch |
| Net Income | -12,180 | -6,280 | -5,120 | -2,590 | -5,790 |
| Net Income Growth | -93.95% | -22.66% | -97.68% | +55.27% | -66.38% |
Scisparc Ltd (SPRC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company. It focuses on the development of therapies to treat disorders of the central nervous system. The company's product pipeline includes SCI-110, SCI-160 and SCI-210. SciSparc Ltd. is based in TEL AVIV, Israel.
Fiscal Year End Date: 12/31